Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Last updated: May 14, 2025
Sponsor: AbbVie
Overall Status: Active - Recruiting

Phase

N/A

Condition

Follicular Lymphoma

Lymphoma

Lymphoproliferative Disorders

Treatment

N/A

Clinical Study ID

NCT06830759
P24-903
  • Ages > 18
  • All Genders

Study Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.

Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.

Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants who are scheduled to be treated with epcoritamab for Treatment aftertwo or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).

  • Treatment with epcoritamab should be administered in accordance with the approvedlocal label in the participating country.

  • The decision to treat the participant should have been made by the clinician priorto, and independently of any decision to approach the participant to participate inthis study.

Exclusion

Exclusion Criteria:

  • Any condition included in the contraindications section of the approved localepcoritamab label in the participating country.

  • Participation in a concurrent interventional clinical trial (not includingnon-interventional/ observational study, PMOS, or registry participation) fromenrollment and throughout the study.

Study Design

Total Participants: 700
Study Start date:
March 28, 2025
Estimated Completion Date:
September 30, 2031

Connect with a study center

  • Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288

    Graz, Steiermark 8020
    Austria

    Active - Recruiting

  • Cross Cancer Institute /ID# 271504

    Edmonton, Alberta T6G 1Z2
    Canada

    Active - Recruiting

  • Health Sciences North /ID# 274738

    Sudbury, Ontario P3E 5J1
    Canada

    Active - Recruiting

  • Evangelismos Hospital /ID# 272736

    Athens, Attiki 10676
    Greece

    Active - Recruiting

  • General Hospital of Athens Laiko /ID# 272758

    Athens, Attiki 11527
    Greece

    Active - Recruiting

  • University General Hospital of Alexandroupoli /ID# 272737

    Alexandroupoli, Evros 68100
    Greece

    Active - Recruiting

  • Papageorgiou General Hospital /ID# 272735

    Thessaloniki, 56429
    Greece

    Active - Recruiting

  • Rabin Medical Center /ID# 271614

    Petah Tikva, 4941492
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.